Chan Heng Fai Ambrose Amends DSS, Inc. Ownership Filing

TL;DR

Chan Heng Fai Ambrose just updated his DSS, Inc. ownership filing (13D/A).

AI Summary

On December 12, 2024, Chan Heng Fai Ambrose filed an amendment (Amendment No. 19) to Schedule 13D for DSS, Inc. This filing indicates a change in beneficial ownership of the company's common stock. The filing does not specify the exact number of shares or the percentage of ownership change in this amendment.

Why It Matters

Changes in beneficial ownership filings like this can signal shifts in control or significant investment activity by major shareholders, potentially impacting stock price and corporate strategy.

Risk Assessment

Risk Level: medium — Schedule 13D/A filings often indicate significant stake changes by large investors, which can lead to volatility.

Key Players & Entities

• Chan Heng Fai Ambrose (person) — Filer of the Schedule 13D/A
• DSS, INC. (company) — Subject company of the filing
• Alset International Limited (company) — Associated with the filer's address

FAQ

Key Financial Figures

• $0.02 — me of Issuer) Common Stock, par value $0.02 per share (Title of Class of Securiti
• $0.9749 — ;s common stock for a purchase price of $0.9749 per share; and (v) that on December 10,

Filing Documents

• formsc13da.htm (SC 13D/A) — 103KB
• 0001493152-24-049867.txt ( ) — 104KB

Purpose of Transaction

Item 4. Purpose of Transaction

of the Schedule 13D is hereby amended

Item 4 of the Schedule 13D is hereby amended to include the following: On December 10, 2024, Alset Inc. entered into a stock purchase agreement with the Issuer, pursuant to which Alset Inc. agreed to purchase 820,597 newly issued shares of the Issuer’s common stock for a purchase price of $0.9749 per share. Alset Inc. and its various subsidiaries are collectively the largest shareholder of DSS. Mr. Chan is the Executive Chairman of DSS and a significant shareholder of DSS. On December 10, 2024, Mr. Chan Heng Fai entered into a stock purchase agreement with the Issuer, pursuant to which Mr. Chan agreed to purchase 205,149 newly issued shares of the Issuer’s common stock for a purchase price of $0.9749 per share. Mr. Chan is the Executive Chairman of DSS and a significant shareholder of DSS.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer (a)-(b) The responses to Items 7 - 13 of the cover pages of this Schedule 13D are incorporated herein by reference. (c) None. (d) None (e) N/A Item 7. Material to be Filed as Exhibits. Exhibit 99.1 Joint Filing Agreement between Heng Fai Chan, Global Biomedical Pte. Ltd. and Alset Inc., incorporated by reference to Amendment No. 13 to the Schedule 13D filed on September 20, 2021. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: December 12, 2024 /s/ Heng Fai Ambrose Chan Name: Heng Fai Ambrose Chan Alset Inc. /s/ Heng Fai Ambrose Chan Name: Heng Fai Ambrose Chan Title: Chief Executive Officer Global Biomedical Pte. Ltd. /s/ Heng Fai Ambrose Chan Name: Heng Fai Ambrose Chan Title: Director Alset International Limited /s/ Heng Fai Ambrose Chan Name: Heng Fai Ambrose Chan Title: Chief Executive Officer

View Full Filing

View this SC 13D/A filing on SEC EDGAR